Challenges with connected devices evolution: There continues to be development and interest in the connected device space though there are still significant challenges for big pharma players trying to adapt to a new digital world. Whilst these devices aim to improve patient engagement, increase adherence, and facilitate better communication among patients and healthcare providers, the commercial strategy for many solutions is much less clear.
Large volume infusion continues to grow: Large volume infusion and in home infusion continues to see growth and is poised to have significant impact on the parenteral drug delivery device landscape in the coming years, offering slower and more stable delivery. Target delivery volumes continue to increase with Halozyme sharing a clinical study demonstrating subcutaneous administration of 10 mL in ~30s.
AI advancements: The applications of AI in the drug delivery space are still very much in their infancy, but there continues to be growing interest and research in this area. One such area discussed at the conference was the use of computational biology to design better delivery systems and discover better targets which has the potential to drastically reduce development time and improve efficacy.
As advancements in the healthcare sector continue to grow, ultimately the developments within drug delivery technology are inevitable, as well as being essential for patients and users. We look forward to seeing what progress is made within this area of the medical industry, and playing our part to enable and drive these developments.
